Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Clinical Trials

Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children with Palmoplantar Wart

Not Applicable

Not yet recruiting

Conditions: Common Warts

Interventions: Drug: Topical 5% fluorouracil cream
Drug: Topical 0.005% calcipotriol ointment
Drug: Placebo

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06737406

Locations: 🇮🇷
Iran, Sari, Mazandaran, Iran, Islamic Republic of

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Atezolizumab
Drug: Irinotecan (CPT-11)
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil (5-FU)

First Posted Date: 2024-12-13

Last Posted Date: 2025-05-07

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 238

Registration Number: NCT06733038

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy
🇮🇹
Azienda Ospedaliero Universitaria Policlinico Rodolico - S. Marco, Catania, CT, Italy
🇮🇹
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, FC, Italy

and more 14 locations

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2

Recruiting

Conditions: HER2-positive Gastric Cancer
Metastatic Gastric Cancer
Unresectable Gastric Carcinoma

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: S-1
Drug: Capecitabine
Drug: 5-FU
Drug: Cisplatin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-31

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 110

Registration Number: NCT06730373

Locations: 🇨🇳
Shandong Univerisity Qilu Hospital, Jinan, Shandong, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Jinan Third People's Hospital, Jinan, Shandong, China

and more 17 locations

Carac & PDT Combination in the Treatment Of Actinic Keratoses

Phase 1

Completed

Conditions: Actinic Keratoses

Interventions: Drug: Fluorouracil
Procedure: Photodynamic therapy
Procedure: Carac in combination with PDT

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: Skin Laser & Surgery Specialists

Target Recruit Count: 60

Registration Number: NCT06712381

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-1826
Drug: SHR-4642
Drug: SHR-9839
Drug: SHR-8068
Drug: Bevacizumab Injection
Drug: Fluorouracil Injection
Drug: Calcium Folinate Injection
Drug: Adebrelimab Injection

First Posted Date: 2024-11-25

Last Posted Date: 2025-02-27

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 876

Registration Number: NCT06703177

Locations: 🇨🇳
Sun Yat-Sen university cancer center, Guangzhou, Guangdong, China

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Phase 3

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma

Interventions: Combination Product: ASP-1929 Photoimmunotherapy
Biological: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: 5-fluorouracil
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2024-11-21

Last Posted Date: 2025-05-04

Lead Sponsor: Rakuten Medical, Inc.

Target Recruit Count: 412

Registration Number: NCT06699212

Locations: 🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung City, Taiwan

and more 9 locations

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase 1

Recruiting

Conditions: Metastatic Colorectal Adenocarcinoma
Stage III Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Emavusertib
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography